Ekso Bionics (EKSO)
(Delayed Data from NSDQ)
$1.18 USD
+0.02 (1.72%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.19 +0.01 (0.85%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EKSO 1.18 +0.02(1.72%)
Will EKSO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EKSO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EKSO
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Ekso Bionics (EKSO) Is a Great 'Buy the Bottom' Stock Now
EKSO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for January 31st
New Strong Buy Stocks for January 31st
Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Other News for EKSO
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
Ekso Bionics receives payment determination for medical reimbursement from CMS
Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session